Brief: Lyell Immunopharma Says Entered Into Second Amendment To Collaboration And License Agreement With GSK

Lyell Immunopharma

17/12/2021 21:56

Dec 17 (Reuters) - Lyell Immunopharma Inc  LYEL.O :
    * LYELL IMMUNOPHARMA - ON DEC 16, CO ENTERED INTO SECOND
AMENDMENT
TO COLLABORATION AND LICENSE AGREEMENT WITH GSK
    * LYELL IMMUNOPHARMA - UNDER AMENDMENT, TO MANUFACTURE
NY-ESO-1 +
EPI-R TCR CELL THERAPY PRODUCT CANDIDATE FOR EPI-R TRIAL AT
BOTHELL FACILITY
    * LYELL IMMUNOPHARMA - COLLABORATION AMENDMENT SPECIFIES
THAT
LYELL OWNS IMPROVEMENTS TO THE EPI-R AND GEN-R TECHNOLOGIES
    * LYELL IMMUNOPHARMA -UNDER AMENDMENT, ELIGIBLE TO RECEIVE
MILESTONE PAYMENTS FOR ANY USE OF ANTI-EXHAUSTION COMPONENT
RELATED TO A COLLABORATION TARGET

Further company coverage:  LYEL.O 

 ((Reuters.Briefs@thomsonreuters.com;))